Progress in heavy ion cancer therapy at IMP and future development

Qiang Li; Xinguo Liu; Zhongying Dai; Pengbo He; Yuanyuan Ma; Guosheng Shen; Xiaodong Jin; Fei Ye; Xiaogang Zheng; Ting Zhao; Hui Zhang; Zheng Li; Bingwen Zou; Yuehu Pu; Weiqiang Chen

doi:10.1002/msp2.22

PDF(1073 KB)

Malignancy Spectrum ›› 2024, Vol. 1 ›› Issue (2) : 91-98. DOI: 10.1002/msp2.22

REVIEW

Progress in heavy ion cancer therapy at IMP and future development

Qiang Li¹^,²^,³^,⁴ ,
Xinguo Liu¹^,²^,³^,⁴ ,
Zhongying Dai¹^,²^,³^,⁴ ,
Pengbo He¹^,²^,³^,⁴ ,
Yuanyuan Ma¹^,²^,³^,⁴ ,
Guosheng Shen¹^,²^,³^,⁴ ,
Xiaodong Jin¹^,²^,³^,⁴ ,
Fei Ye¹^,²^,³^,⁴ ,
Xiaogang Zheng¹^,²^,³^,⁴ ,
Ting Zhao¹^,²^,³^,⁴ ,
Hui Zhang¹^,²^,³^,⁴ ,
Zheng Li⁵ ,
Bingwen Zou⁵ ,
Yuehu Pu⁶ ,
Weiqiang Chen¹^,²^,³^,⁴

Author information +

History +

Abstract

Basic research on heavy ion cancer therapy such as radiobiology, medical physics, and therapeutic technique has been conducted at the Institute of Modern Physics (IMP), Chinese Academy of Sciences since 1995. Based on the achievements acquired in the basic research and the requirements for a heavy ion accelerator for radiotherapy purposes, a dedicated heavy ion therapy facility named Heavy Ion Medical Machine (HIMM) was designed at IMP and constructed in Wuwei, China. The HIMM facility consists of two electron cyclotron resonance ion sources, one cyclotron as the injector and one synchrotron as the main accelerator, and four different treatment rooms equipped with passive or active beam delivery systems, and accelerates carbon ions up to 400 MeV/u. After the performance inspection of HIMM organized by the National Medical Device Inspection Center, preclinical tests like cell and animal radiobiological experiments and dosimetric verification using anthropomorphic phantoms for elucidating the biophysical properties of the carbon ion beams provided by HIMM were carried out. According to the Chinese medical device regulations, a clinical trial in which 46 tumor patients were recruited and two hospitals participated was conducted in the HIMM facility, aiming at evaluating the treatment safety and short-term efficacy of the medical device. The success of the clinical trial helped the HIMM facility be authorized by the Chinese government as a class III medical device. In this paper, all the aspects mentioned above are introduced and discussed, and implications for future improvements are also given.

Keywords

heavy ion cancer therapy / clinical trial / performance inspection / dosimetric verification / medical device

Cite this article

EndNote

Ris (Procite)

Bibtex

Download citation ▾

Qiang Li, Xinguo Liu, Zhongying Dai, Pengbo He, Yuanyuan Ma, Guosheng Shen, Xiaodong Jin, Fei Ye, Xiaogang Zheng, Ting Zhao, Hui Zhang, Zheng Li, Bingwen Zou, Yuehu Pu, Weiqiang Chen. Progress in heavy ion cancer therapy at IMP and future development. Malignancy Spectrum, 2024, 1(2): 91‒98 https://doi.org/10.1002/msp2.22